Roth Capital Downgrades Seelos Therapeutics (SEEL) to Neutral, Following Clinical Business Update
Tweet Send to a Friend
Roth Capital analyst Jonathan Aschoff downgraded Seelos Therapeutics (NASDAQ: SEEL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
